Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Rhea-AI Summary
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company developing precision oncology medicines for serious unmet medical needs, announced management participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026.
The company’s presentation, led by Chairman and CEO Ron Bentsur, is scheduled from 9:00–9:30 AM EDT in New York, NY. A live webcast will be accessible in the Investors section of the Nuvectis website.
Positive
- None.
Negative
- None.
News Market Reaction – NVCT
In the May 14 session, NVCT gained 3.41%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.0% during that session. Argus tracked a trough of -14.3% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Q1 2026 earnings | Positive | +9.2% | Reported Q1 2026 results and NXP900 updates with cash of $25.1M. |
| Mar 31 | AACR presentations | Positive | +3.2% | Announced multiple AACR 2026 poster presentations for NXP900 in oncology. |
| Feb 11 | 2025 earnings | Positive | +0.5% | Reported 2025 results with cash funding milestones into second half 2027. |
| Dec 17 | Phase 1b initiation | Positive | -1.4% | Initiated Phase 1b NXP900 plus osimertinib study in EGFRmut+ NSCLC patients. |
| Nov 25 | KOL meeting | Positive | +1.7% | Planned virtual KOL meeting to review NXP900 Phase 1b data and strategy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows NVCT often trading positively on news, especially around financial updates and NXP900 program milestones. Four of the last five covered events saw positive 24-hour price reactions, including earnings and clinical news, with only one divergence where a Phase 1b initiation coincided with a modest decline. This pattern suggests that investors have generally responded favorably to the company’s disclosures and development updates.
Over the past six months, NVCT has reported multiple catalysts tied to its NXP900 program and financial runway. Q1 2026 results on May 5, 2026 highlighted cash of $25.1M and a planned Phase 1b readout in summer 2026, with shares rising 9.22%. Earlier, 2025 results on Feb 11, 2026 emphasized funding into 2H 2027. Clinical milestones included a Phase 1b osimertinib combination study initiation on Dec 17, 2025. Today’s conference participation fits this ongoing pattern of active investor communication around development progress.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.
Conference Details:
Date: Tuesday, May 19, 2026
Company Presentation: 9:00 – 9:30AM EDT
Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis
Webcast Link: here
Location: New York, NY
A webcast of the presentation will be available in the Investors section of Nuvectis’ website at www.nuvectis.com.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing NXP900, a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study, a drug-drug interaction study in healthy volunteers and the Phase 1b program is ongoing.
Company Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
